oxaliplatin + capecitabine + sorafenib

Combination regimen of the platinum chemotherapeutic oxaliplatin, the oral fluoropyrimidine prodrug capecitabine, and the multikinase inhibitor sorafenib. Oxaliplatin forms DNA crosslinks leading to apoptosis. Capecitabine is converted to 5‑fluorouracil, inhibiting thymidylate synthase and RNA/DNA synthesis. Sorafenib inhibits RAF kinases and multiple receptor tyrosine kinases involved in tumor proliferation and angiogenesis, including VEGFR and PDGFR. Studied in phase I–II trials using a 2-day high-dose capecitabine plus oxaliplatin schedule (2DOC) with sorafenib for pancreatic adenocarcinoma, establishing a recommended phase II dose and showing partial responses with manageable toxicity. A randomized phase II trial evaluated the regimen (SECOX) versus sorafenib alone in advanced hepatocellular carcinoma. XELOX/CAPOX (oxaliplatin + capecitabine) is an established chemotherapy backbone to which sorafenib is added in these studies.[1][2][4][9]

Other names

2DOC + sorafenibSECOXsorafenib + oxaliplatin + capecitabine